Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a three-arm, multicenter, randomized controlled trial. Eligible participants will be randomized to one of three induction regimens via stratified block randomization at a 2:2:1 ratio. Induction regimens: Arm A: Teniposide + orelabrutinib + rituximab + methotrexate (MTX) + dexamethasone, administered in 21-day cycles. Arm B: Orelabrutinib + rituximab + MTX + dexamethasone, administered in 21-day cycles. Arm C: Rituximab + MTX + dexamethasone, administered in 21-day cycles. Participants achieving complete response (CR) or unconfirmed complete response (CRu) post-induction will proceed to consolidation therapy, with options including: MTX + rituximab (once every 3 months for 1 year); high-dose chemotherapy followed by autologous stem cell transplantation (ASCT); dose-reduced whole brain radiotherapy; or other modalities (as determined by the investigator).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-75 lat
- •Chłoniak potwierdził biopsia (typ DLBCL)
- •Brak poprzedniego leczenia tego schorzenia
- •Dobre funkcjonowanie narządów wewnętrznych (wątroba, nerki)
- •Zdolność do tolerowania punkcji plever lub posiadania rezerwuaru Ommaya
- •Brak komórek białaczkowych we krwi obwodowej
- •Oczekiwany czas przeżycia co najmniej 3 miesiące
- •Pisemna zgoda na uczestnictwo w badaniu
✗ Disqualifies
- •Chłoniak rozprzestrzeniający się poza mózg i rdzeń kręgowy
- •Wcześniejsza historia innych nowotworów
- •Chłoniak w oku lub podejrzenie chłoniaka w oku
- •Poważne choroby serca (niewydolność, nieustabilizowana choroba wieńcowa)
- •Niekontrolowane zaburzenia krzepnięcia krwi
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- August 19, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (15)
Peking University Third Hospital
Beijing, China
Xuanwu Hospital
Beijing, China
Huaxi Hospital
Chengdu, China
First Affiliated Hospital of Fujian Medical University
Fuzhou, China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou, China
Department of Hematology, Qilu Hospital of Shandong University
Jinan, China
The First Affiliated Hospital of Nanchang University
Nanchang, China
The Tumor Hospital of Jiangsu Province
Nanjing, China
Changhai Hospital
Shanghai, China
Huashan Hospital
Shanghai, China
RenJi Hospital
Shanghai, China
Shanghai Tongji Hospital, Tongji University School of Medicine
Shanghai, China
WuhanUnionHospital
Wuhan, China
Tang-Du Hospital
Xi'an, China
Henan Cancer Hospital
Zhengzhou, China
Trial contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/19/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.